Bryan Neth, MD, PhD

Neuro-Oncology + Behavioral Neurology @mayoclinic | @mayoneurores + @WakeForest + @floridastate alum | Science. Art. Flavor. | Views are my own

[Amy Robinson Sterling @amyneurons]

Click anywhere on the brain and see that region's projections.
Fibers are diffusion tractography (dMRI) from Human Connectome Project
https://t.co/Fl4O6YnbiB

[Joshua D. Palmer, MD @joshuapalmermd]

Check out our phase 2 trial using Memory avoidant (MA)WBRT, improved cognitive preservation compare to historical HA-WBRT. Out now in Neuro Onc advances

https://t.co/hUxXWFG4Po

[PDBrown @PDBrownOnc]

🚨🚨Randomized Trial: How does Hypofraction compare to Standard of Care Stupp regimen for GBM?
POORLY, according to the Gold trial with worse OS and increased radiation necrosis https://t.co/8ul9s4Bpls

[Marcus Pinto, MD, MS @MarcusVPinto]

The recommendation to perform serum SPEP with immunofixation in every case of distal symmetric polyneuropathy has caused unnecessary harm to patients. This advice has been repeated so often that many regard it as an absolute truth. However, Dr. Go and colleagues from @MayoClinic Hematology demonstrate the very low clinical utility of monoclonal gammopathy testing in patients with peripheral neuropathy. https://t.co/dNpWGKskCR

[Eytan Ruppin, MD, PhD @EytanRuppin]

🚨 Out today in Cell! @CellCellPress

Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale.

📄 https://t.co/GtrmH9zIDs

🧵1/8

[Divyanshu Dubey @Div_Dubey]

Grateful for our team effort featured by Mayo Clinic News Network—developing a blood test to detect germ cell tumors missed by standard markers.
https://t.co/HR7nFfaJJa

[Danny Arends @DannyArends]

Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan.

https://t.co/EoeexqJoHk

59 loci. Two decades of data. Thread 👇

#Longevity #Aging #Genetics #Healthspan

[gelareh-zadeh @gelarehzadeh]

Honored to have a @NatRevClinOncol publication on the work we & colleagues have done on #meningiomas
Research & discoveries improving #care #clinicaltrials
@ICOMeningioma @MeningiomaBot
RT 🙏🏻 @mayoclinic @MayoRadOnc @MayoCancerCare @MayoClinicNeuro
Thanking all #collaborators

[Alberto Vogrig @Vogrig_Alberto]

Why do only some cancer patients develop #paraneoplastic neurological syndromes (PNS)? 🧠
This review explores the immune mechanisms behind PNS and how tumor genetics & immune tolerance shape risk. Kudos to @AKunchok. Open access link: https://t.co/glF1CAIhn5

[PDBrown @PDBrownOnc]

Should we treat higher SRS doses for brainstem mets (than the typical lower doses used)?
Tumor control probability MODELING:
1 Yr 90%LC 18.9 Gy/1, 25.7/3, 28.6/5
2 Yr 90%LC 20.5 Gy/1, 28.2/3, 31.5/5
https://t.co/mipCmC609f

[PDBrown @PDBrownOnc]

Editorial CATNON IDHmt Grade 3 Astrocytoma
· NO benefit concurrent temozolomide
· Sig benefit w/adjuvant TMZ
· MGMT NOT prognostic
· Poor prog CDKN2A/B homo deletion, PDGFRA amp, methy profile
https://t.co/e8wGebVHFI

[PDBrown @PDBrownOnc]

What is the long term control Sporadic Vestibular Schwannoma after radiosurgery?
LC 5, 10, & 15 years 96%, 92%, & 91%
13% pseudoprogression median time 0.5 yrs (only 4% >5yr after SRS) https://t.co/x4MHXTUNC9

[nature @Nature]

For decades, researchers have noted that cancer and Alzheimer’s disease are rarely found in the same person

https://t.co/rgYalgRdfi

[Journal of Neuro-Oncology @JNeurooncol]

Gonzalez-Aponte et al. reported circadian rhythms in MGMT promoter methylation and protein levels in GBM, with peaks at midday and CT4, respectively, predicting time-of-day differences in temozolomide efficacy. #JNO

Read more:https://t.co/2eDZ6vL8fo

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

Also this came out today!

https://t.co/uN3TJQ3AVc

[PDBrown @PDBrownOnc]

Cognitive recovery after radiation brain mets meta-analysis
· 1/3 cognitive recovery @6mo after initial decline
· Recovery more likely if SRS or HA-WBRT compared to WBRT
https://t.co/S7aeKaiHAA

[Nir Lipsman @DrNirLipsman]

A decade after our world-first BBB opening for #GBM, our newest trial shows FUS is safe, well-tolerated, with signals of benefit.

A major milestone for a devastating illness.

Grateful to @INSIGHTEC, @FUSFoundation, our donors, and brave patients.

https://t.co/eoBYfieJQR

[Lyell Jones MD @LyellJ]

Coming soon, our first ever issue dedicated to…

[Bryan Neth, MD, PhD @bryanneth]

Longevity science has hit the mainstream—but no one agrees on the science https://t.co/hDvo9Hrl9c

[Ian F. Parney MD PhD @IanParneyMDPhD]

This is a great description of what is was like for ⁦@BobbyMukkamala⁩, incoming AMA President and ENT surgeon, to have an awake craniotomy. ⁦@MayoClinicNeuro⁩ ⁦@MayoClinic⁩ https://t.co/907ljr5qGJ